Anavex Life Science setting up for Bull run Phase 2 Data
Anavex Life Sciences is up on almost 50% higher volume in reaction to the results from a study evaluating the gut microbiota of Alzheimer's patients enrolled in its Phase 2a extension study of ANAVEX 2-73.
The analysis showed that patients receiving ANAVEX 2-73, a sigma-1 receptor (S1R) agonist, had high levels of two gut microbiota families that were associated with improved daily living activities at week 148.
CEO Christopher Missling, Ph.D. says, “This is the first gut microbiota DNA sequencing analysis of Alzheimer’s disease patients treated with ANAVEX 2-73 which might help to identify potential biomarkers of response for ANAVEX 2-73. We continue to advance the ANAVEX 2-73 Alzheimer’s disease program through the ongoing Phase 2b/3 Alzheimer’s disease clinical study and in other ongoing ANAVEX 2-73 clinical trials focused on serious neurology diseases with high unmet needs, including Rett syndrome and Parkinson’s disease dementia.” Source Seeking Alpha.
AVERAGE ANALYSTS PRICE TARGET $10
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO
SHORT INTEREST 9%
COMPANY PROFILE
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
The analysis showed that patients receiving ANAVEX 2-73, a sigma-1 receptor (S1R) agonist, had high levels of two gut microbiota families that were associated with improved daily living activities at week 148.
CEO Christopher Missling, Ph.D. says, “This is the first gut microbiota DNA sequencing analysis of Alzheimer’s disease patients treated with ANAVEX 2-73 which might help to identify potential biomarkers of response for ANAVEX 2-73. We continue to advance the ANAVEX 2-73 Alzheimer’s disease program through the ongoing Phase 2b/3 Alzheimer’s disease clinical study and in other ongoing ANAVEX 2-73 clinical trials focused on serious neurology diseases with high unmet needs, including Rett syndrome and Parkinson’s disease dementia.” Source Seeking Alpha.
AVERAGE ANALYSTS PRICE TARGET $10
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO
SHORT INTEREST 9%
COMPANY PROFILE
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Comment:
Past performance is not an indicator of future returns. TopMarketGainers is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. TopMarketGainers has purchased up to 10,000 shares of AVXLand intends to sell for a profit in the future. Never make investment decisions based on anything TopMarketGainers says. This message is meant for informational and educational purposes only and does not provide investment advice.
Comment:
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media